Introduction

The heart has four chambers; the right and left atria and right and left ventricles. The heart also has valves that help with blood circulation, the mitral and tricuspid valves are called “atrioventricular” because of their location that is between the atriums and ventricles, and the aortic and pulmonary valves are the “arterioventricular” valves located between the ventricles and arteries. (Figure-1) The name of the mitral valve derives from the liturgical headgear (miter) of the Catholic/Christian tradition. The mitral valve also called bicuspid valve, is located between the left atrium and left ventricle and is composed of the mitral annulus, papillary muscles, anterior leaflet, and posterior leaflet and chordae tendinae, all these components form the valve apparatus which prevents the blood backflow from the left ventricle to the left atrium during systole, and during diastole allows normal blood flow from the left atrium to the left ventricle.[1] 

Structure and Function

The main feature of the mitral valve is the mitral apparatus, which is composed of the left atrial wall, left ventricle wall, the mitral annulus, the anterior and posterior leaflets, chordae tendinae and papillary muscles. The mechanical and metabolic balance of the valve is guaranteed by the presence of interstitial cells, which are very sensitive to mechanical information (mechanotransduction) and help in valve remodeling. The valve surface is rich in endothelial cells that communicate with interstitial cells to maintain the strength and shape of the valve.

Mitral annulus: The mitral annulus is a fibrous ovoid ring located around the mitral opening, it works as a sphincter; it contracts during systole and reduces the mitral valve area by completely closing the leaflets. At the posterior leaflet insertion, the mitral annulus is thinner than other parts of the annulus, making it more vulnerable to dilatation and resulting in inadequate leaflet closure. When severe dilation occurs, the leaflets are unable to approximate each other, and mitral regurgitation is the result.[2]

Leaflets: Unlike the tricuspid valve, the mitral valve has two leaflets, the anterior leaflet, and the posterior leaflet.

The anterior leaflet is located at the posterior part of the aortic root and also fixed to it. The anterior leaflet corresponds to one-third of the annular ring and two-thirds of the valvular orifice approximately. The anterior leaflet is a semicircular shape and has a free edge without indentations; it is larger and thicker compared with the posterior leaflet. It has two zones, the rough zone and clear zone that are separated by a ridge on the atrial surface. This prominent ridge is located 1 cm from the edge of the anterior leaflet. During systole, the rough zone of the anterior leaflet will be adjacent to the posterior leaflet.[2][3]

The posterior leaflet comprises the other two-thirds of the annular circumference and also has the name ventricular or mural leaflet. It is in the posterior part of the two commissural areas. Different from the anterior leaflet, the posterior leaflet divides into three areas zones or segments, the basal, the clear, and the rough zones, defined as P1, P2, and P3. The rough zone is distal to the ridge and broadest at the scallops. Similar to the anterior leaflet, the clear zone in the posterior leaflet is clear on transillumination and is in the middle between the basal and rough zone. The basal zone only exists in the posterior leaflet and is located at the middle scallop between the mitral annulus and clear zone.[4] 

From the histological point of view, one can distinguish three layers in the leaflets of the mitral valve:

• The fibrosa, which is rigid and superficial with thick collagen fibers
• The atrial, which is thinner and towards the atrial surface, with elastic fibers
• The spongiosa, a layer consisting in particular of glycosaminoglycans (GAG) and proteoglycans.

Finally, there is another very thin layer of elastic fibers on the ventricular side, in continuity with the elastic fabric of the chordae tendinae.

Chordae tendinae:

Are part of the subvalvular apparatus, the chordae tendinae are composed of fibrous strings that originate from the papillary muscles or the ventricle wall and that its insertion is into the ventricle, the anterior leaflet, posterior leaflet, and commissural leaflet. Two kinds of chordae tendinae are distinguished based on their insertion into the leaflets. The primary or marginal chordae are thinner and are attached to the leaflets at the free edge, preventing leaflet edge to prolapse for its characteristic of being high collagen fibers with reduced tension.[5][6] The secondary or intermediary chordae are thicker than primary chordae and are more extensible due to the more tightly collagen they have. The secondary chordae are attached to the ventricle aspect of the leaflets and help to reduce tension at the leaflet.[7][8]  

The chordae consist mainly of elastin and crimped collagen fibers. Chordae tendinae can have six classifications: depending on the origin they can be apical and basal; depending on the area concerned, true or false; depending on the anatomical attack they are cusp, cleft and commissural; depending on the interest of the valve area they are first-order chordae or second-order chordae; depending on the shape they can be straight, branched, dichotomous or irregular; and depending on the constitution they can be tendinous, muscular, or membranous.

Embryology

The embryologic formation of the mitral valve is not well understood. It appears that the development of the most rudimentary valve starts after the tube heart has just developed after the second week of gestation.

The heart develops myocardial and endothelial layers that form an extracellular matrix. At the end of week 4 of fetal life, the extracellular matrix forms the basic four chambers, and by week 5, the outer part of the myocardial layer is compacted to form trabecular structures that will become the left ventricle. At this time,  the common atrioventricular canal and the cardiac cushions (lateral, superior, and inferior) can be detected.[9][10] The cardiac cushions are composed of fibroblast cells that are endothelial cells in the mesenchyme and form the endothelial-mesenchymal transformation.[9]

At week 5 of fetal life, the inferior and superior cushions fuse to divide into two portions, left and right, the common atrioventricular canal. When the superior and inferior cushion are fused, the anterior leaflet of the mitral valve forms and the left lateral cushions form the posterior leaflet.[11][10]

The left ventricle trabecular bridges develop between weeks 8 to 10, and the lateral and medial papillary muscles are formed by week 10 and are observable in the left ventricle cavity, both muscles are attached to leaflet forming cushions. Between week 11 through week 13, papillary muscled continue to grow and develop chordae. Mitral valve apparatus (leaflets, chordae, and papillary muscles) complete development by week 15 and keep growing until all the demands of the organism are complete.[10]

Blood Supply and Lymphatics

Two papillary muscles are part of the mitral valve, the anterior and posterior papillary muscles, and each of them provides tendon cords for both valve leaflets. The anterior papillary muscle receives vascular supply via the anterior descending artery and the circumflex artery, which is a branch of the left coronary artery, while branches of the right coronary artery vascularize the posterior papillary muscle. Dysfunction of blood supply can damage the valve.[12]

Nerves

The autonomic nervous system modulates the mechanical properties of the mitral valve, thanks to the release of neurotransmitters from nerve ends. The stiffness of the valve decreases in the presence of acetylcholine, while it increases in the presence of norepinephrine.[13] Aging reduces valve innervation.

Muscles

The main muscular structures that are part of the mitral apparatus are the papillary muscles and the left ventricular wall. The papillary muscles derive their names from their relationship with the mitral commissures. They originate from the apical portion of the left ventricle, and there are two, the anterolateral papillary muscle and the posteromedial papillary muscle.[12][14] 

The papillary muscles system coordinates with the mitral annulus, so in every contraction during systole, this system prevents leaflet prolapse.[15][13][12][16][14] As part of the mitral apparatus, the papillary muscles and all the other components of mitral apparatus work in a way to maintain valvular competence and the proper blood flow. On the other hand, if a fusion of the papillary muscles exists, it will result in stenosis of the mitral valve, and if there is a rupture of the papillary muscles, common as a complication of myocardial infarction, will result in mitral regurgitation.[16]

Physiologic Variants

The main non-pathological anatomical variants are the presence of scallops (29.5%). The variations occur most commonly in the posterior area. The anterior mitral leaflet may have an accessory scallop (2.5%).

Surgical Considerations

Mitral Regurgitation is associated with an abnormal backflow of blood from the left ventricle to the left atrium. In developed countries, the main cause is ischemic coronary disease, and in undeveloped countries, the main cause is a rheumatic disease. Mitral regurgitation in the United States is present in approximately 2 million people and is the second most common valvular disease, after aortic stenosis.[17]

In functional mitral regurgitation the mitral valve leaflets and the mitral annulus apparatus are normal, but there is an abnormality of the ventricular wall, that results in a dysfunction between the wall motion, the papillary muscles and the annulus that increases the distance of the annulus and papillary muscles that results in the restriction of the leaflet motion. On the other hand, rheumatic mitral regurgitation is an acquired disease that presents with stenosis of the mitral valve, in this case, the leaflets are thickened and rigid, the chordae tendinae become shortened due to fibrosis as a result of inflammatory changes. There is also calcification of the leaflets and the mitral valve apparatus that can result in leaflet dysfunction and causes leaflet motion restriction and regurgitation.[18][19][17][20] 

Symptoms of mitral regurgitation depend on the left ventricle function; patients can present with dyspnea, fatigue, and orthopnea. Patients with severe disease can progress to congestive heart failure with pulmonary congestion and edema. On auscultation of a patient with mitral regurgitation, the S1 may appear diminished, and a classic finding is a holosystolic, high-pitched murmur due to early closure of the aortic valve.[19][20]

Mitral Valve Prolapse (MVP) is defined as the displacement of one or more leaflets by more than 2 mm into the left atrium during ventricular systole, and most commonly is a manifestation of myxomatous degenerative disease of the mitral valve.[21][22] The lack of connective tissue support caused by the myxomatous degeneration causes chordal rupture and diffuse thickening of the leaflets that results in an ineffective leaflet coaptation during systole.[23][21] Mitral valve prolapse is a common condition and also an important risk factor for developing mitral regurgitation, congestive heart failure, arrhythmia, and endocarditis. However, most patients with mitral valve prolapse have a minor alteration of the mitral valve apparatus that is clinically insignificant.[23] Most patients with mitral valve prolapse are asymptomatic and the diagnosis is often made on examination of a patient with the classic mid-to-late systolic click and murmur heard on auscultation. It also may be diagnosed by echocardiography.[21][22]

Mitral Stenosis is defined as the narrowing of the mitral valve apparatus; the most common cause is rheumatic heart disease and develops years after the first episode of rheumatic carditis. The normal orifice of the mitral valve area is 4 to 6 cm^2. Patients with mitral stenosis will experience symptoms when the area of the valve is 2.5 cm^2 or less.[24][25] Severe mitral stenosis is considered when the area is less than 1 cm^2. As the area of the mitral valve narrows, the left atrial pressure, increases. This can lead to transudation of fluid into the lung interstitium and will cause dyspnea at rest or with exertion. The main treatment for mitral stenosis is to avoid the recurrence of rheumatic fever, so prophylaxis against group A beta-hemolytic streptococci is recommended.[24][25] The symptoms of mitral stenosis most commonly manifest during the third or fourth decade of life, patients with atrial fibrillation can develop embolic episodes. Patients can also develop hoarseness due to compression of the left recurrent laryngeal nerve by the enlarged left atrium.[26][27]

Indications and surgical treatment

Once the severity of the valve defect has been established, an indication for surgery includes all symptomatic patients, with normal or reduced ventricular function, and in asymptomatic or paucisymptomatic patients in whom there is evidence of contractile dysfunction. The choice of surgical timing is based on clinical and instrumental data, as well as on the evaluation of the operating risks and the preference of the patient himself. Also, the possibility of predicting the type of intervention, reparative or replacement, will condition the surgical timing. The ideal time would be to intervene before an irreversible compromise of the ventricular function is achieved. In fact, following an operation performed late, often severe dysfunction of the left ventricle persists, which portends a poor prognosis; on the contrary, an operation performed early, especially if it consists of a repair, involves a low operative risk and allows the patient a quality and life expectancy not different from the normal population. The advantages of repair over replacement include improvements in survival, the lower perioperative mortality and the better preservation of the post-operative ejection fraction, as demonstrated by several studies that have been published in the last decade.

When valvular repair is not considered feasible, mitral valve replacement with preservation of the subvalvular structures is considered the next option. Indeed, when the subvalvular apparatus is not preserved during mitral replacement surgery, the post-surgical sphericity of the left ventricle increases; this unfavorable geometric change explains the decrease in the post-operative ejection fraction compared to the substitution intervention with preservation of the subvalvular apparatus.

In considering specifically the degenerative pathology, the degree of the feasibility of the reparative intervention is very high, being executable in more than 90% of the patients. Estimates are that over 80% of valves are repairable; in highly specialized centers, more than 90% of operations on the ischemic mitral valve are performed through reparative methods.

In the specific case of ischemic mitral valve insufficiency, in patients with severe valve defects, the correction of the valve pathology in association with coronary artery bypass is certainly recommended, in particular, valve repair.

Clinical Significance

The mitral valve is an elaborate anatomical structure composed of the interaction between each valvular component, along with the left atrial myocardium and left ventricle, and each of these components plays a different and vital roll in the function of the mitral valve. Mitral regurgitation one of the most common pathologies, and it can present because of leaflet abnormalities caused by rheumatic or degenerative disease, or it may be secondary due to left ventricle dysfunction caused by dilated or ischemic cardiomyopathy with normal mitral valve structure.[19] Knowledge of anatomy and understanding the normal function of the mitral valve structure is crucial for assessing valve failure and its mechanism. This knowledge, in turn, will help with clinical case implementation and better treatments of mitral valve repair with better long term results.

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Rajput FA, Zeltser R. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 29, 2023. Aortic Valve Replacement. [PubMed: 30725821]

2.

Schubert SA, Mehaffey JH, Charles EJ, Kron IL. Mitral Valve Repair: The French Correction Versus the American Correction. Surg Clin North Am. 2017 Aug;97(4):867-888. [PMC free article: PMC5567844] [PubMed: 28728720]

3.

Carpentier AF, Lessana A, Relland JY, Belli E, Mihaileanu S, Berrebi AJ, Palsky E, Loulmet DF. The "physio-ring": an advanced concept in mitral valve annuloplasty. Ann Thorac Surg. 1995 Nov;60(5):1177-85; discussion 1185-6. [PubMed: 8526596]

4.

Dal-Bianco JP, Levine RA. Anatomy of the mitral valve apparatus: role of 2D and 3D echocardiography. Cardiol Clin. 2013 May;31(2):151-64. [PMC free article: PMC3856635] [PubMed: 23743068]

5.

Liao J, Vesely I. A structural basis for the size-related mechanical properties of mitral valve chordae tendineae. J Biomech. 2003 Aug;36(8):1125-33. [PubMed: 12831738]

6.

Lam JH, Ranganathan N, Wigle ED, Silver MD. Morphology of the human mitral valve. I. Chordae tendineae: a new classification. Circulation. 1970 Mar;41(3):449-58. [PubMed: 5415982]

7.

Millington-Sanders C, Meir A, Lawrence L, Stolinski C. Structure of chordae tendineae in the left ventricle of the human heart. J Anat. 1998 May;192 ( Pt 4)(Pt 4):573-81. [PMC free article: PMC1467811] [PubMed: 9723984]

8.

Degandt AA, Weber PA, Saber HA, Duran CM. Mitral valve basal chordae: comparative anatomy and terminology. Ann Thorac Surg. 2007 Oct;84(4):1250-5. [PubMed: 17888977]

9.

Armstrong EJ, Bischoff J. Heart valve development: endothelial cell signaling and differentiation. Circ Res. 2004 Sep 03;95(5):459-70. [PMC free article: PMC2810618] [PubMed: 15345668]

10.

Oosthoek PW, Wenink AC, Wisse LJ, Gittenberger-de Groot AC. Development of the papillary muscles of the mitral valve: morphogenetic background of parachute-like asymmetric mitral valves and other mitral valve anomalies. J Thorac Cardiovasc Surg. 1998 Jul;116(1):36-46. [PubMed: 9671895]

11.

Schoen FJ. Evolving concepts of cardiac valve dynamics: the continuum of development, functional structure, pathobiology, and tissue engineering. Circulation. 2008 Oct 28;118(18):1864-80. [PubMed: 18955677]

12.

RUSTED IE, SCHEIFLEY CH, EDWARDS JE. Studies of the mitral valve. I. Anatomic features of the normal mitral valve and associated structures. Circulation. 1952 Dec;6(6):825-31. [PubMed: 12998105]

13.

Gorman JH, Gupta KB, Streicher JT, Gorman RC, Jackson BM, Ratcliffe MB, Bogen DK, Edmunds LH. Dynamic three-dimensional imaging of the mitral valve and left ventricle by rapid sonomicrometry array localization. J Thorac Cardiovasc Surg. 1996 Sep;112(3):712-26. [PubMed: 8800160]

14.

Victor S, Nayak VM. Variations in the papillary muscles of the normal mitral valve and their surgical relevance. J Card Surg. 1995 Sep;10(5):597-607. [PubMed: 7488788]

15.

Komeda M, Glasson JR, Bolger AF, Daughters GT, Ingels NB, Miller DC. Papillary muscle-left ventricular wall "complex". J Thorac Cardiovasc Surg. 1997 Feb;113(2):292-300; discussion 300-1. [PubMed: 9040623]

16.

CHIECHI MA, LEES WM, THOMPSON R. Functional anatomy of the normal mitral valve. J Thorac Surg. 1956 Sep;32(3):378-98. [PubMed: 13358125]

17.

Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. Lancet. 2009 Apr 18;373(9672):1382-94. [PubMed: 19356795]

18.

Otsuji Y, Handschumacher MD, Schwammenthal E, Jiang L, Song JK, Guerrero JL, Vlahakes GJ, Levine RA. Insights from three-dimensional echocardiography into the mechanism of functional mitral regurgitation: direct in vivo demonstration of altered leaflet tethering geometry. Circulation. 1997 Sep 16;96(6):1999-2008. [PubMed: 9323092]

19.

Sabbah HN, Rosman H, Kono T, Alam M, Khaja F, Goldstein S. On the mechanism of functional mitral regurgitation. Am J Cardiol. 1993 Nov 01;72(14):1074-6. [PubMed: 8213590]

20.

Sabbah HN, Kono T, Stein PD, Mancini GB, Goldstein S. Left ventricular shape changes during the course of evolving heart failure. Am J Physiol. 1992 Jul;263(1 Pt 2):H266-70. [PubMed: 1636764]

21.

Guy TS, Hill AC. Mitral valve prolapse. Annu Rev Med. 2012;63:277-92. [PubMed: 22248324]

22.

Sanfilippo AJ, Harrigan P, Popovic AD, Weyman AE, Levine RA. Papillary muscle traction in mitral valve prolapse: quantitation by two-dimensional echocardiography. J Am Coll Cardiol. 1992 Mar 01;19(3):564-71. [PubMed: 1538011]

23.

Feldman T, Kar S, Rinaldi M, Fail P, Hermiller J, Smalling R, Whitlow PL, Gray W, Low R, Herrmann HC, Lim S, Foster E, Glower D., EVEREST Investigators. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol. 2009 Aug 18;54(8):686-94. [PubMed: 19679246]

24.

Oehler AC, Sullivan PD, Mansoor AM. Mitral Stenosis. BMJ Case Rep. 2017 May 15;2017 [PMC free article: PMC5534921] [PubMed: 28512104]

25.

Chandrashekhar Y, Westaby S, Narula J. Mitral stenosis. Lancet. 2009 Oct 10;374(9697):1271-83. [PubMed: 19747723]

26.

Zaky A, Nasser WK, Feigenbaum H. A study of mitral valve action recorded by reflected ultrasound and its application in the diagnosis of mitral stenosis. Circulation. 1968 May;37(5):789-99. [PubMed: 5646862]

27.

Padmavati S. Rheumatic fever and rheumatic heart disease in India at the turn of the century. Indian Heart J. 2001 Jan-Feb;53(1):35-7. [PubMed: 11456138]

Disclosure: Felipe Sanchez Vaca declares no relevant financial relationships with ineligible companies.

Disclosure: Bruno Bordoni declares no relevant financial relationships with ineligible companies.